Literature DB >> 7591115

Evaluation of formalin-inactivated Clostridium difficile vaccines administered by parenteral and mucosal routes of immunization in hamsters.

J F Torres1, D M Lyerly, J E Hill, T P Monath.   

Abstract

Clostridium difficile produces toxins that cause inflammation, necrosis, and fluid in the intestine and is the most important cause of nosocomial antibiotic-associated diarrhea and colitis. We evaluated C. difficile antigens as vaccines to protect against systemic and intestinal disease in a hamster model of clindamycin colitis. Formalin-inactivated culture filtrates from a highly toxigenic strain were administered by mucosal routes (intranasal, intragastric, and rectal) with cholera toxin as a mucosal adjuvant. A preparation of culture filtrate and killed whole cells was also tested rectally. The toxoid was also tested parenterally (subcutaneously and intraperitoneally) and by a combination of three intranasal immunizations followed by a combined intranasal-intraperitoneal boost. Serum antibodies against toxins A and B and whole-cell antigen were measured by enzyme-linked immunosorbent assay, neutralization of cytotoxic activity, and bacterial agglutination. The two rectal immunization regimens induced low antibody responses and protected only 20% of hamsters against death and 0% against diarrhea. The intragastric regimen induced high antibody responses but low protection, 40% against death and 0% against diarrhea. Hamsters immunized by the intranasal, intraperitoneal, and subcutaneous routes were 100% protected against death and partially protected (40, 40, and 20%, respectively) against diarrhea. Among the latter groups, intraperitoneally immunized animals had the highest serum anticytotoxic activity and the highest agglutinating antibody responses. Hamsters immunized intranasally and revaccinated intraperitoneally were 100% protected against both death and diarrhea. Protection against death and diarrhea correlated with antibody responses to all antigens tested. The results indicate that optimal protection against C. difficile disease can be achieved with combined parenteral and mucosal immunization.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7591115      PMCID: PMC173664          DOI: 10.1128/iai.63.12.4619-4627.1995

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  44 in total

1.  Effect of toxin A and B of Clostridium difficile on rabbit ileum and colon.

Authors:  T J Mitchell; J M Ketley; S C Haslam; J Stephen; D W Burdon; D C Candy; R Daniel
Journal:  Gut       Date:  1986-01       Impact factor: 23.059

2.  Is Clostridium difficile endemic in chronic-care facilities?

Authors:  B S Bender; R Bennett; B E Laughon; W B Greenough; C Gaydos; S D Sears; M S Forman; J G Bartlett
Journal:  Lancet       Date:  1986-07-05       Impact factor: 79.321

3.  The effects of Clostridium difficile crude toxins and toxin A on ileal and colonic loops in immune and non-immune rabbits.

Authors:  J M Ketley; T J Mitchell; D C Candy; D W Burdon; J Stephen
Journal:  J Med Microbiol       Date:  1987-08       Impact factor: 2.472

4.  Active and passive immunization to protect against antibiotic associated caecitis in hamsters.

Authors:  D S Fernie; R O Thomson; I Batty; P D Walker
Journal:  Dev Biol Stand       Date:  1983

5.  Factors influencing the phagocytosis of Clostridium difficile by human polymorphonuclear leukocytes.

Authors:  D C Dailey; A Kaiser; R H Schloemer
Journal:  Infect Immun       Date:  1987-07       Impact factor: 3.441

6.  Protection against experimental pseudomembranous colitis in gnotobiotic mice by use of monoclonal antibodies against Clostridium difficile toxin A.

Authors:  G Corthier; M C Muller; T D Wilkins; D Lyerly; R L'Haridon
Journal:  Infect Immun       Date:  1991-03       Impact factor: 3.441

7.  Effects of the two toxins of Clostridium difficile in antibiotic-associated cecitis in hamsters.

Authors:  J M Libby; B S Jortner; T D Wilkins
Journal:  Infect Immun       Date:  1982-05       Impact factor: 3.441

8.  Serum antibody response to toxins A and B of Clostridium difficile.

Authors:  R Viscidi; B E Laughon; R Yolken; P Bo-Linn; T Moench; R W Ryder; J G Bartlett
Journal:  J Infect Dis       Date:  1983-07       Impact factor: 5.226

9.  Interaction between Clostridium difficile and polymorphonuclear leucocytes from the elderly and post-operative cancer patients: phagocytosis and bactericidal function.

Authors:  H P Bassaris; P E Lianou; N J Legakis; J T Papavassiliou
Journal:  Med Microbiol Immunol       Date:  1984       Impact factor: 3.402

10.  Effects of Clostridium difficile toxins given intragastrically to animals.

Authors:  D M Lyerly; K E Saum; D K MacDonald; T D Wilkins
Journal:  Infect Immun       Date:  1985-02       Impact factor: 3.441

View more
  36 in total

1.  New method to generate enzymatically deficient Clostridium difficile toxin B as an antigen for immunization.

Authors:  H Genth; J Selzer; C Busch; J Dumbach; F Hofmann; K Aktories; I Just
Journal:  Infect Immun       Date:  2000-03       Impact factor: 3.441

Review 2.  The potential for emerging therapeutic options for Clostridium difficile infection.

Authors:  Harsh Mathur; Mary C Rea; Paul D Cotter; R Paul Ross; Colin Hill
Journal:  Gut Microbes       Date:  2014

3.  Safety and immunogenicity of increasing doses of a Clostridium difficile toxoid vaccine administered to healthy adults.

Authors:  K L Kotloff; S S Wasserman; G A Losonsky; W Thomas; R Nichols; R Edelman; M Bridwell; T P Monath
Journal:  Infect Immun       Date:  2001-02       Impact factor: 3.441

Review 4.  Vaccines against Clostridium difficile.

Authors:  Rosanna Leuzzi; Roberto Adamo; Maria Scarselli
Journal:  Hum Vaccin Immunother       Date:  2014-03-17       Impact factor: 3.452

5.  Protection against Clostridium difficile infection with broadly neutralizing antitoxin monoclonal antibodies.

Authors:  Andre J Marozsan; Dangshe Ma; Kirsten A Nagashima; Brian J Kennedy; Yun Kenneth Kang; Robert R Arrigale; Gerald P Donovan; Wells W Magargal; Paul J Maddon; William C Olson
Journal:  J Infect Dis       Date:  2012-06-25       Impact factor: 5.226

Review 6.  Antibodies for treatment of Clostridium difficile infection.

Authors:  David P Humphreys; Mark H Wilcox
Journal:  Clin Vaccine Immunol       Date:  2014-04-30

7.  Immunization with Bacillus spores expressing toxin A peptide repeats protects against infection with Clostridium difficile strains producing toxins A and B.

Authors:  Patima Permpoonpattana; Huynh A Hong; Jutarop Phetcharaburanin; Jen-Min Huang; Jenny Cook; Neil F Fairweather; Simon M Cutting
Journal:  Infect Immun       Date:  2011-04-11       Impact factor: 3.441

8.  Development and optimization of a novel assay to measure neutralizing antibodies against Clostridium difficile toxins.

Authors:  Jinfu Xie; Julie Zorman; Lani Indrawati; Melanie Horton; Keri Soring; Joseph M Antonello; Yuhua Zhang; Susan Secore; Matthew Miezeiewski; Su Wang; Anthony D Kanavage; Julie M Skinner; Irene Rogers; Jean-Luc Bodmer; Jon H Heinrichs
Journal:  Clin Vaccine Immunol       Date:  2013-02-06

9.  Mechanisms of protection against Clostridium difficile infection by the monoclonal antitoxin antibodies actoxumab and bezlotoxumab.

Authors:  Zhiyong Yang; Jeremy Ramsey; Therwa Hamza; Yongrong Zhang; Shan Li; Harris G Yfantis; Dong Lee; Lorraine D Hernandez; Wolfgang Seghezzi; Jamie M Furneisen; Nicole M Davis; Alex G Therien; Hanping Feng
Journal:  Infect Immun       Date:  2014-12-08       Impact factor: 3.441

10.  Protective efficacy induced by recombinant Clostridium difficile toxin fragments.

Authors:  Rosanna Leuzzi; Janice Spencer; Anthony Buckley; Cecilia Brettoni; Manuele Martinelli; Lorenza Tulli; Sara Marchi; Enrico Luzzi; June Irvine; Denise Candlish; Daniele Veggi; Werner Pansegrau; Luigi Fiaschi; Silvana Savino; Erwin Swennen; Osman Cakici; Ernesto Oviedo-Orta; Monica Giraldi; Barbara Baudner; Nunzia D'Urzo; Domenico Maione; Marco Soriani; Rino Rappuoli; Mariagrazia Pizza; Gillian R Douce; Maria Scarselli
Journal:  Infect Immun       Date:  2013-05-28       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.